Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | 0.07 | 0.07 | -0.10 |
| FCF Yield | -65.07% | -22.38% | -37.54% | -101.61% |
| EV / EBITDA | -7.26 | -9.65 | -5.73 | -2.61 |
| Quality | ||||
| ROIC | -34.22% | -27.23% | -59.47% | -51.08% |
| Gross Margin | 84.71% | 82.20% | 80.12% | 78.94% |
| Cash Conversion Ratio | 1.04 | 0.82 | 1.07 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 51.32% | 94.08% | 36.48% | 9.46% |
| Free Cash Flow Growth | -36.04% | 53.13% | 22.70% | -65.29% |
| Safety | ||||
| Net Debt / EBITDA | -4.99 | -4.31 | -1.99 | -1.43 |
| Interest Coverage | -2.55 | -2.36 | -3.73 | -7.05 |
| Efficiency | ||||
| Inventory Turnover | 1.39 | 1.95 | 0.59 | 0.30 |
| Cash Conversion Cycle | 367.11 | 195.29 | 669.57 | 993.28 |